Profile picture of Tim Clay

A/Prof Tim Clay

Profile picture of Tim Clay

MBBS (Hons UWA), DMedSci (U Melb), FRACP

Medical Oncologist
Call
Enquire
Referrals

A/Prof Tim Clay brings an extensive clinical research background to his practice and has a strong belief in the role of clinical research advancing patient care.

Biography

A/Prof Tim Clay is an experienced medical oncologist at Icon Cancer Centre Midland. He graduated from the University of Western Australia and completed basic physician training at Royal Perth Hospital. A/Prof Clay subsequently commenced specialist oncology training at Geelong Hospital and St Vincent’s Hospital Melbourne and completed a doctoral thesis on lung cancer pathology at the University of Melbourne.

In addition to clinical practice he enjoys advancing cancer care through clinical trials of new therapies and supportive care interventions like exercise. A/Prof Clay is also active teaching junior doctors, nurses and allied health staff, and Adjunct Associate Professor at Edith Cowan University. His clinical experience covers a broad range of solid tumour malignancies with special interest in breast cancer, thoracic cancers (including lung cancer), genitourinary cancers (prostate cancer, bladder cancer, kidney cancer, testis cancer) and colorectal cancer. A/Prof Clay does not accept referrals for gynaecological cancers, sarcoma or CNS malignancies.

A/Prof Clay is married and has three children. In his spare time he enjoys watching motor racing, soccer and Australian music.

Publications

  • Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. E. Segelov, C. Underhill, H. Prenen, C. Karapetis, C. Jackson, L. Nott, T. Clay, N. Pavlakis S. Sabesan, E. Heywood, C. Steer, C. Lethborg, H.K. Gan, D. Yip, N. Karanth, D. Karikios & C.R. MacIntyre. JCO Oncology Practice, 2020; 16(8): 467-482.

  • Keeping Patients With Cancer Exercising in the Age of COVID-19. R.U. Newton, N.H. Hart & T. Clay. JCO Oncology Practice, 2020l 16(10): 656-664.

  • Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. N.H. Hart, D.A. Galvão, C. Saunders, D.R. Taaffe, K.T. Feene, N.A. Spry, D. Tsoi, H. Martin, R. Chee, T. Clay, A.D. Redfern & R.U. Newton. Trials, 2018; 19(1): 695.

  • The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. T. Clay, H. Do, V. Sundararajan, M.M. Moore, M. Conron, G.M. Wright, S.A. McLachlan, A. Dobrovic & P.A. Russell PA. Journal of Thoracic Oncology, 201; 9(5): 654-663. 

     

Special Interests

A/Prof Tim Clay accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Colorectal cancer
  • Genitourinary cancer
  • Lung cancer
  • Prostate cancer

Languages spoken

  • English

Icon Locations

Visiting Locations

  • St John of God Subiaco Hospital

Affiliations & Memberships

  • Australasian Gastro-Intestinal Trials Group (AGITG)
  • Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
  • Australian Medical Association (AMA)
  • Breast Cancer Trials
  • Clinical Oncology Society of Australia (COSA)
  • Medical Oncology Group of Australia (MOGA)
  • Private Cancer Physicians of Australia (PCPA)
  • Royal Australasian College of Physicians (RACP)
  • Thoracic Oncology Group of Australia (TOGA)

Publications

  • Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. E. Segelov, C. Underhill, H. Prenen, C. Karapetis, C. Jackson, L. Nott, T. Clay, N. Pavlakis S. Sabesan, E. Heywood, C. Steer, C. Lethborg, H.K. Gan, D. Yip, N. Karanth, D. Karikios & C.R. MacIntyre. JCO Oncology Practice, 2020; 16(8): 467-482.

  • Keeping Patients With Cancer Exercising in the Age of COVID-19. R.U. Newton, N.H. Hart & T. Clay. JCO Oncology Practice, 2020l 16(10): 656-664.

  • Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. N.H. Hart, D.A. Galvão, C. Saunders, D.R. Taaffe, K.T. Feene, N.A. Spry, D. Tsoi, H. Martin, R. Chee, T. Clay, A.D. Redfern & R.U. Newton. Trials, 2018; 19(1): 695.

  • The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. T. Clay, H. Do, V. Sundararajan, M.M. Moore, M. Conron, G.M. Wright, S.A. McLachlan, A. Dobrovic & P.A. Russell PA. Journal of Thoracic Oncology, 201; 9(5): 654-663. 

     

Search

Contact us
Become a patient